98 related articles for article (PubMed ID: 38017389)
1. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
2. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
[TBL] [Abstract][Full Text] [Related]
3. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
4. DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.
Yan J; Wang S; Zhang J; Yuan Q; Gao X; Zhang N; Pan Y; Zhang H; Liu K; Yu J; Lu L; Liu H; Gao X; Zhao S; Zhang W; Reyila A; Qi Y; Zhang Q; Cang S; Lu Y; Pan Y; Kong Y; Nie Y
Cancer Biol Med; 2023 Dec; 21(3):252-66. PubMed ID: 38164720
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR; Bolte LA; Maltez Thomas A; Lee KA; Rossi N; Wind TT; Smit LM; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Spector TD; Bataille V; Segata N; Hospers GAP; Weersma RK
Nat Med; 2024 Mar; 30(3):785-796. PubMed ID: 38365950
[TBL] [Abstract][Full Text] [Related]
6. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
Voigt AY; Walter A; Young TH; Graham JP; Batista Bittencourt BM; de Mingo Pulido A; Prieto K; Tsai KY; Sundberg JP; Oh J
Exp Dermatol; 2023 Oct; 32(10):1624-1632. PubMed ID: 37350109
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells.
Pu C; Li Y; Fu Y; Yan Y; Tao S; Tang S; Gai X; Ding Z; Gan Z; Liu Y; Cao S; Wang T; Ding J; Xu J; Geng M; Huang M
Adv Sci (Weinh); 2024 Mar; 11(11):e2304781. PubMed ID: 38189627
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer.
Chang JW; Hsieh JJ; Tsai CY; Chiu HY; Lin YF; Wu CE; Shen YC; Hou MM; Chang CY; Chen JA; Chen CL; Chiu CT; Yeh YM; Chiu CH
Biomed J; 2024 Jan; ():100698. PubMed ID: 38280521
[TBL] [Abstract][Full Text] [Related]
9. A gut microbial signature for combination immune checkpoint blockade across cancer types.
Gunjur A; Shao Y; Rozday T; Klein O; Mu A; Haak BW; Markman B; Kee D; Carlino MS; Underhill C; Frentzas S; Michael M; Gao B; Palmer J; Cebon J; Behren A; Adams DJ; Lawley TD
Nat Med; 2024 Mar; 30(3):797-809. PubMed ID: 38429524
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Absmaier-Kijak M; Iuliano C; Kaesler S; Biedermann T; Posch C; Brockow K
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539560
[TBL] [Abstract][Full Text] [Related]
11. Multi-cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma.
Yan J; Deng L; Yu J; Wu X; Wang S; Cang S
Clin Transl Med; 2023 Nov; 13(11):e1478. PubMed ID: 37987157
[No Abstract] [Full Text] [Related]
12. geneshot: gene-level metagenomics identifies genome islands associated with immunotherapy response.
Minot SS; Barry KC; Kasman C; Golob JL; Willis AD
Genome Biol; 2021 May; 22(1):135. PubMed ID: 33952321
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome is associated with recurrence-free survival in patients with resected Stage IIIB-D or Stage IV melanoma treated with immune checkpoint inhibitors.
Usyk M; Hayes RB; Knight R; Gonzalez A; Li H; Osman I; Weber JS; Ahn J
bioRxiv; 2024 Apr; ():. PubMed ID: 38659744
[TBL] [Abstract][Full Text] [Related]
14. The Importance of Immune Checkpoint Molecule TIGIT in AKI.
Moore KH; Agarwal A
J Am Soc Nephrol; 2023 May; 34(5):725-727. PubMed ID: 36850028
[No Abstract] [Full Text] [Related]
15. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
16. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
17. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
18. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.
Wind TT; Gacesa R; Vich Vila A; de Haan JJ; Jalving M; Weersma RK; Hospers GAP
Melanoma Res; 2020 Jun; 30(3):235-246. PubMed ID: 31990790
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
